Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + lenalidomide
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Daratumumab + lenalidomide is a combination therapy used primarily for the treatment of multiple myeloma, a type of blood cancer. Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of myeloma cells. By binding to CD38, daratumumab induces cell death through several mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct induction of apoptosis via Fc receptor-mediated crosslinking. Lenalidomide is an immunomodulatory agent with antiangiogenic properties; it enhances immune effector cell function and inhibits tumor growth by preventing new blood vessel formation in tumors. The combination has demonstrated significant efficacy in prolonging progression-free survival in patients with relapsed or refractory multiple myeloma[1][2][5][6].
- Other names
- DRd
02
Targets
CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on daratumumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + lenalidomide.